Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Confirmed diagnosis of: * Postmenopausal advanced hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer after failure of treatment with letrozole or anastrozole * Progressive neuroendocrine tumors of pancreatic origin (PNET) that is unresectable, locally advanced or metastatic * Advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib * Histologically confirmed, measurable or evaluable disease. Patients should have at least one measurable lesion. * Adequate bone marrow function as indicated by the following: * Absolute neutrophil count (ANC) \> 1,500/μL * Platelets ≥ 100,000/μL * Hemoglobin \> 10 g/dL * Adequate renal function, as indicated by creatinine clearance \> 30 mL/min * Adequate liver function, as indicated by: * Bilirubin ≤ 1.5 x upper limit of normal (ULN) * International normalized ratio (INR) ≤ 2 * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 2 x ULN unless related to primary disease * Signed informed consent * Adequate birth control when appropriate * Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication. Exclusion Criteria: * Patients currently receiving antican…